<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>702</ReferenceId>
        <DateLastUpdated>2016-11-03-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15320877</PubmedId>
            <Abstract>Cell-mediated immune responses are crucial in the protection against tuberculosis. In this study, we constructed epitope DNA vaccines (p3-M-38) encoding cytotoxic T lymphocyte (CTL) epitopes of MPT64 and 38 kDa proteins of Mycobacterium tuberculosis. In order to observe the influence of spacer sequence (Ala-Ala-Tyr) or ubiquitin (UbGR) on the efficacy of the two CTL epitopes, we also constructed DNA vaccines, p3-M-S(spacer)-38, p3-Ub (UbGR)-M-S-38 and p3-Ub-M-38. The immune responses elicited by the four DNA vaccines were tested in C57BL/6 (H-2b) mice. The cytotoxicity of T cells was detected by LDH-release method and by enzyme-linked immunospot assay for epitope-specific cells secreting interferon-gamma. The results showed that DNA immunization with p3-M-38 vaccine could induce epitope-specific CD8+ CTL response and that the spacer sequence (AAY) only enhanced M epitope presentation. The protein-targeting sequence (UbGR) enhanced the immunogenicity of the two epitopes. The finding that defined spacer sequences at C-terminus and protein-targeting degradation modulated the immune response of epitope string DNA vaccines will be of importance for the further development of multi-epitope DNA vaccines against tuberculosis.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>219-25</ArticlePages>
            <ArticleTitle>Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Q-M</ForeName>
                </Author>
                <Author>
                    <LastName>Sun</LastName>
                    <ForeName>S-H</ForeName>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Z-L</ForeName>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>F-J</ForeName>
                </Author>
                <Author>
                    <LastName>Yin</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Xiao</LastName>
                    <ForeName>C-J</ForeName>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>J-C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Medical Genetics, The Second Military Medical University, Shanghai, China.</Affiliations>
            <ArticleChemicalList>Epitopes;Tuberculosis Vaccines;Ubiquitin;Vaccines, DNA;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Epitopes(immunology); Female; Immunity, Cellular(immunology; physiology); Interferon-gamma(metabolism); Mice; Mycobacterium tuberculosis(immunology); T-Lymphocytes(immunology; metabolism); T-Lymphocytes, Cytotoxic(immunology); Transfection; Tuberculosis(immunology; prevention &amp; control); Tuberculosis Vaccines(immunology); Ubiquitin(immunology; metabolism); Vaccines, DNA(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>60</Volume>
                <Issue>3</Issue>
                <Title>Scandinavian journal of immunology</Title>
                <Issn>1365-3083</Issn>
                <MedlineTa>Scand J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>M epitope</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FAVTNDGVI</LinearSequence>
                        <StartingPosition>190</StartingPosition>
                        <EndingPosition>198</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P0A5Q4.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 3</LocationOfData>
                <EpitopeId>15302</EpitopeId>
                <ReferenceStartingPosition>190</ReferenceStartingPosition>
                <ReferenceEndingPosition>198</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4A</LocationOfData>
                        <TCellId>6989</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FAVTNDGVI</LinearSequence>
                                            <StartingPosition>190</StartingPosition>
                                            <EndingPosition>198</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5Q4.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>p3M-38 construct</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 dose(s) of 50 ug plasmid DNA in 50 ul PBS</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Four multi-epitope constructs of M + 38 epitopes with or without a spacer sequence (AAY) and/or with or without ubiquitin (UbGR) were used as immunogens in separate vaccinations; both quadriceps of animals were injected; 25% sucrose was also injected beforehand to the muscles to enhance DNA uptake; interval between innoculations is 3 weeks. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>EL-4 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>167</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M epitope</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAVTNDGVI</LinearSequence>
                                        <StartingPosition>190</StartingPosition>
                                        <EndingPosition>198</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5Q4.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>575</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>A cytotoxicity assay measuring LDH release was performed. All vaccine constructs containing the epitope induced cytotoxicity in target cells. The greatest induction occurred when both spacer sequence and ubiquitin were included in the construct.  EL-4 cells target cells that stably express MPT64 (source antigen) after transfection were used.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>6988</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FAVTNDGVI</LinearSequence>
                                            <StartingPosition>190</StartingPosition>
                                            <EndingPosition>198</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5Q4.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>p3M-38 construct</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 dose(s) of 50 ug plasmid DNA in 50 ul PBS</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Four multi-epitope constructs of M + 38 epitopes with or without a spacer sequence (AAY) and/or with or without ubiquitin (UbGR) were used as immunogens in separate vaccinations; both quadriceps of animals were injected; 25% sucrose was also injected beforehand to the muscles to enhance DNA uptake; interval between innoculations is 3 weeks. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>167</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M epitope</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAVTNDGVI</LinearSequence>
                                        <StartingPosition>190</StartingPosition>
                                        <EndingPosition>198</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5Q4.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>All vaccine constructs containing the epitope induced CTLs. The greatest induction occurred when both spacer sequence and ubiquitin were included in the construct.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>38 epitope</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IAALNPGVNL</LinearSequence>
                        <StartingPosition>166</StartingPosition>
                        <EndingPosition>175</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P15712.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 3</LocationOfData>
                <EpitopeId>25227</EpitopeId>
                <ReferenceStartingPosition>166</ReferenceStartingPosition>
                <ReferenceEndingPosition>175</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4B</LocationOfData>
                        <TCellId>6991</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>IAALNPGVNL</LinearSequence>
                                            <StartingPosition>166</StartingPosition>
                                            <EndingPosition>175</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P15712.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>p3M-38 construct</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 dose(s) of 50 ug plasmid DNA in 50 ul PBS</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Four multi-epitope constructs of M + 38 epitopes with or without a spacer sequence (AAY) and/or with or without ubiquitin (UbGR) were used as immunogens in separate vaccinations; both quadriceps of animals were injected; 25% sucrose was also injected beforehand to the muscles to enhance DNA uptake; interval between innoculations is 3 weeks. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>EL-4 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>167</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>38 epitope</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAALNPGVNL</LinearSequence>
                                        <StartingPosition>166</StartingPosition>
                                        <EndingPosition>175</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P15712.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>575</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>A cytotoxicity assay measuring LDH release was performed. All vaccine constructs containing the epitope induced cytotoxicity in target cells. The greatest induction occurred when both spacer sequence and ubiquitin were included in the construct.  EL-4 cells target cells that stably express 38 kD antigen (same as source antigen) after transfection were used.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>6990</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>IAALNPGVNL</LinearSequence>
                                            <StartingPosition>166</StartingPosition>
                                            <EndingPosition>175</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P15712.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>p3M-38 construct</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 dose(s) of 50 ug plasmid DNA in 50 ul PBS</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Four multi-epitope constructs of M + 38 epitopes with or without a spacer sequence (AAY) and/or with or without ubiquitin (UbGR) were used as immunogens in separate vaccinations; both quadriceps of animals were injected; 25% sucrose was also injected beforehand to the muscles to enhance DNA uptake; interval between innoculations is 3 weeks. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>167</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>38 epitope</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAALNPGVNL</LinearSequence>
                                        <StartingPosition>166</StartingPosition>
                                        <EndingPosition>175</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P15712.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>All vaccine constructs containing the epitope induced CTLs The greatest induction occurred when ubiquitin was included in the construct.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

